What’s Up with Molly (MDMA) After the Executive Order? |
Take our Depression Test
Find a therapist to heal from trauma
The recent presidential Executive Order on psychedelic therapies has intensified the debate on MDMA.
MDMA is the primary example of an empathogen—inducing empathy, openness, and interpersonal connection.
MDMA is a drug of abuse and both promising and challenging medication for treating severe PTSD.
The Executive Order may reposition the VA/DoD as major research infrastructure for MDMA studies.
Few compounds better illustrate the tension between therapeutic promise, regulatory skepticism, abuse liability, and political momentum surrounding post-traumatic stress disorder (PTSD) than the drug MDMA, a drug that acts as both a stimulant and a hallucinogen (empathogen and an entactogen) known by the street names Ecstasy and Molly. At one time primarily associated with rave culture, it is used to change energy, mood, empathy, distort time perception, and enhance the enjoyment of tactile experiences and pleasure. MDMA continues to be studied as a potentially transformative psychiatric intervention for PTSD.
The recent presidential Executive Order on psychedelic therapies did not legalize MDMA, nor did it bypass FDA authority. Instead, it may have shifted where the future of psychedelic psychiatry will ultimately be decided. The Executive Order apparently repositions the Department of Veterans Affairs (VA) and the Department of Defense (DoD) as major research infrastructures for psychedelic medicine.
This means that the future of MDMA-assisted therapy may depend less on advocacy groups and much more on whether federally supervised studies on veterans and active-duty military personnel demonstrate durable, standardized, and clinically meaningful outcomes.
From “Molly” to Medicine
Historically, MDMA referred to pressed tablets sold in dance clubs, while “Molly” became shorthand for supposedly pure crystalline MDMA. In reality, however, forensic analyses have repeatedly shown that illicit products sold as MDMA are often adulterated with methamphetamine, synthetic cathinones, ketamine analogs, caffeine, cocaine, or fentanyl.
MDMA became widely known as the “love drug” because of its empathogenic effects. Users frequently reported increased emotional openness, heightened interpersonal trust, reduced defensiveness, and stronger feelings of emotional connection. These same effects also raised concerns regarding emotional suggestibility, compromised judgment, and vulnerability to exploitation.
This double identity—as a possible therapeutic agent and a recreational drug of abuse—continues shaping MDMA’s regulatory history.
As a recent editorial in the journal Lancet (2026) observed, the principal challenge facing psychedelic psychiatry is to “separate hope firmly from hype.” The editorial noted that psychedelic-assisted therapy trials remain difficult to blind effectively (or to hide what they are, so subjects can’t tell whether they took the study drug or the placebo). Importantly, however, the editorial characterized many FDA concerns regarding MDMA-assisted psychotherapy as “remediable issues".
Why the FDA Rejected MDMA in 2024
Early randomized trials demonstrated unusually large effect sizes in patients with severe and treatment-resistant PTSD, including veterans, first responders, and survivors of chronic trauma. Phase-2 and Phase-3 studies showed substantial reductions in Clinician-Administered PTSD Scale (CAPS) scores, and the pivotal MAPP1 trial published in Nature Medicine in 2021 became a landmark for psychedelic psychiatry.
Despite this impetus, the FDA declined to approve MDMA-assisted therapy in 2024.
The FDA was less concerned........